GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HLB Therapeutics Co Ltd (XKRX:115450) » Definitions » Return-on-Tangible-Asset

HLB Therapeutics Co (XKRX:115450) Return-on-Tangible-Asset : 0.38% (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is HLB Therapeutics Co Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. HLB Therapeutics Co's annualized Net Income for the quarter that ended in Mar. 2024 was ₩638 Mil. HLB Therapeutics Co's average total tangible assets for the quarter that ended in Mar. 2024 was ₩166,682 Mil. Therefore, HLB Therapeutics Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was 0.38%.

The historical rank and industry rank for HLB Therapeutics Co's Return-on-Tangible-Asset or its related term are showing as below:

XKRX:115450' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -23.17   Med: -12.68   Max: 10.66
Current: -1.25

During the past 13 years, HLB Therapeutics Co's highest Return-on-Tangible-Asset was 10.66%. The lowest was -23.17%. And the median was -12.68%.

XKRX:115450's Return-on-Tangible-Asset is ranked better than
82.27% of 1551 companies
in the Biotechnology industry
Industry Median: -40.12 vs XKRX:115450: -1.25

HLB Therapeutics Co Return-on-Tangible-Asset Historical Data

The historical data trend for HLB Therapeutics Co's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLB Therapeutics Co Return-on-Tangible-Asset Chart

HLB Therapeutics Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -22.93 -23.17 -18.05 -9.21 -1.92

HLB Therapeutics Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.84 9.46 -3.01 -13.22 0.38

Competitive Comparison of HLB Therapeutics Co's Return-on-Tangible-Asset

For the Biotechnology subindustry, HLB Therapeutics Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLB Therapeutics Co's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HLB Therapeutics Co's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where HLB Therapeutics Co's Return-on-Tangible-Asset falls into.



HLB Therapeutics Co Return-on-Tangible-Asset Calculation

HLB Therapeutics Co's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-2302.158/( (118836.218+121411.667)/ 2 )
=-2302.158/120123.9425
=-1.92 %

HLB Therapeutics Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=638.232/( (121411.667+211953.051)/ 2 )
=638.232/166682.359
=0.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


HLB Therapeutics Co  (XKRX:115450) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


HLB Therapeutics Co Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of HLB Therapeutics Co's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


HLB Therapeutics Co (XKRX:115450) Business Description

Traded in Other Exchanges
N/A
Address
22F, Parkview Tower, 6, Jeongja-Dong, Bundang-Gu, Seongnam-si, 463-863, KOR, 463-811
HLB Therapeutics Co Ltd is a bio company that pursues first-in-class and innovates new drug development. With the development and validation of new drugs for various hard-to-treat disorders, HLB Therapeutics is becoming a global biopharmaceutical company focused on alleviating patient suffering.

HLB Therapeutics Co (XKRX:115450) Headlines

No Headlines